Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of PF-08634404 in resectable or unresectable locally advanced non-small cell lung cancer
MOH_2026-07-16_016938Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PF-08634404 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Started Jul 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2026-07-16_016938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-16_016938.